These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31770546)

  • 21. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current status of artisanal cannabis for the treatment of epilepsy in the United States.
    Sulak D; Saneto R; Goldstein B
    Epilepsy Behav; 2017 May; 70(Pt B):328-333. PubMed ID: 28254350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
    Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
    Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol for Epilepsy: New Hope on the Horizon?
    Sanmartin PE; Detyniecki K
    Clin Ther; 2018 Sep; 40(9):1438-1441. PubMed ID: 30150078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research.
    Franco V; Bialer M; Perucca E
    Neuropharmacology; 2021 Mar; 185():108442. PubMed ID: 33347884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
    Samanta D
    Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of cannabidiol in the treatment of epilepsy.
    Mazurkiewicz-Bełdzińska M; Zawadzka M
    Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabidiol treatment of severe refractory epilepsy in children and young adults.
    Zilmer M; Olofsson K
    Dan Med J; 2021 Apr; 68(5):. PubMed ID: 33913416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilepsy and cannabidiol: a guide to treatment.
    Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
    Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
    Montouris G; Aboumatar S; Burdette D; Kothare S; Kuzniecky R; Rosenfeld W; Chung S
    Epilepsy Behav; 2020 Sep; 110():107146. PubMed ID: 32563898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol in the Treatment of Epilepsy.
    von Wrede R; Helmstaedter C; Surges R
    Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
    Dale T; Downs J; Olson H; Bergin AM; Smith S; Leonard H
    Epilepsy Res; 2019 Mar; 151():31-39. PubMed ID: 30771550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
    Press CA; Knupp KG; Chapman KE
    Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.